

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-2 (Canceled)

3. (Currently Amended) A method for screening or selecting at least one cell expressing a polypeptide with a desired binding affinity to a ligand from cells expressing a library of polypeptide variants, comprising:

a) providing a plurality of eukaryotic cells each comprising an expression cassette comprising a first polynucleotide encoding a polypeptide variant, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide downstream of the stop codon;

b) cultivating the cells in the presence of a termination suppression agent under conditions that allow expression of the polypeptide variant, wherein the termination suppression agent is an aminoglycoside antibiotic; and

c) using FACS to select at least one cell expressing the polypeptide variant fused to a cell membrane anchoring peptide based on binding affinity of said polypeptide variant to said ligand.

4-5 (Canceled)

6. (Currently Amended) The method of claim 3, wherein the second polynucleotide encodes a cell membrane anchoring peptide, and wherein the at least one selected cell expresses a fusion protein comprising the polypeptide fused to a cell membrane anchoring peptide, the fusion protein being displayed at the surface of said cell.

7-14 (Canceled)

15. (Currently Amended) The method of claim 3, further comprising:

d) cultivating at least one selected cell in ~~the~~ an absence of a termination suppression agent to obtain expression of the polypeptide as a soluble polypeptide.

Claims 16-57 (Canceled)

58. (Previously Presented) The method of claim 6, wherein the cell membrane anchoring peptide is a GPI anchor.

Claims 59-62 (Canceled)

63. (Previously Presented) The method of claim 4, wherein the aminoglycoside antibiotic is selected from the group consisting of G-418, gentamicin (gentamycin), paromomycin, hygromycin, amikacin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

Claims 64-65 (Canceled)

66. (Previously Presented) The method of claim 3, wherein the second polynucleotide further encodes a reporter peptide.

67. (Previously Presented) The method of claim 3, wherein the second polynucleotide further encodes an epitope tag.

68. (Previously Presented) The method of claim 3, wherein the at least one codon is UAA.

69. (Previously Presented) The method of claim 3, wherein the at least one codon is UGA.

70. (Previously Presented) The method of claim 3, wherein the cells are cultivated in the presence of a butyrate salt.

71. (New) The method of claim 3, wherein the first polynucleotide encodes an antibody or antibody fragment.